4.5200 0.00 (0.00%)
After hours: 5:07PM EDT
|Bid||4.1700 x 2200|
|Ask||4.5200 x 4000|
|Day's Range||4.4300 - 4.7200|
|52 Week Range||3.5000 - 10.4500|
|Beta (3Y Monthly)||1.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.48|
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted eight newly-hired employees options to purchase an aggregate of 277,250 shares of Akebia’s common stock on August 30, 2019, including an option to purchase 250,000 shares granted to Steven K. Burke, M.D., Akebia’s newly-hired Senior Vice President, Chief Medical Officer. The options were granted as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $4.13 per share, which is equal to the closing price of Akebia’s common stock on the grant date.
Unlike commercial-stage companies that have product revenues, drug startups largely rely on private equity funding, stock sales and debt financing to fund their operations. And those operations can be pricey.
If you own shares in Akebia Therapeutics, Inc. (NASDAQ:AKBA) then it's worth thinking about how it contributes to the...
Akebia Therapeutics, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that John P.
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 14.29% and 14.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.-- -- Auryxia ® Revenue Increases to $29.1 Million for Q2’FY19, Up 21% from Q2’FY18 and Up 26% from Q1’FY19; ANDA Settlement Reinforces Strength of Auryxia IP; and, Vadadustat Achieves Key Regulatory Milestone with JNDA Submission Akebia Therapeutics , Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, ...
Akebia Therapeutics, Inc. (AKBA), today announced that its wholly-owned subsidiary, Keryx Biopharmaceuticals, Inc., and its licensor Panion & BF Biotech, Inc., have entered into a Settlement and License Agreement (Agreement) with Par Pharmaceutical, Inc., an Endo International company (Par). This settlement resolves patent litigation brought by Keryx and Panion in response to Par’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Auryxia (ferric citrate) tablets prior to the expiration of the applicable patents.
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The big shareholder groups in Akebia Therapeutics, Inc. (NASDAQ:AKBA) have power over the company. Institutions often...
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA): Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the...
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
AkebiaCares connects patients, caregivers and health care providers with resources and important information to support greater access to therapy
The market has been volatile in the fourth quarter as the Federal Reserve continued its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points. SEC filings and hedge […]